Literature DB >> 8537021

Prevalence of HTLV-I-associated uveitis in the Kanto Plain, Japan.

M Ishioka1, K Goto, S Nakamura, N Watanabe, E Uchio, K Saeki, S Ohno.   

Abstract

BACKGROUND: Seroprevalence of antibody to human T-lymphotropic virus type I (HTLV-I) is high in the island of Kyushu, Japan. Reports on the etiological analysis of HTLV-I in patients with uveitis primarily document cases in this island. We studied the seroprevalence of HTLV-I at the Department of Ophthalmology in Yokohama City University Hospital and in Odawara Municipal Hospital, which are in the Kanto Plain on the island of Honshu, Japan.
METHODS: The subjects were 741 patients who visited the two hospitals. The presence of serum antibodies against HTLV-I was assessed using the method of particle agglutination.
RESULTS: Of 454 patients with nonuveitic ocular diseases, 9 (1.98%) were seropositive. Of 143 patients with definite diagnosis of uveitis, 1 (0.70%) was seropositive. Of 144 patients with non-specific uveitis (etiology undefined), 8 (5.56%) were seropositive. Thus, the prevalence of serum antibodies to HTLV-I was higher in patients with non-specific uveitis than in patients with specific uveitis or nonuveitic ocular diseases. Common ocular symptoms of 8 HTLV-I-infected patients with non-specific uveitis were compatible with the clinical features of uveitis described as HTLV-I-associated uveitis (HAU).
CONCLUSION: It is important to suspect HAU in patients with uveitis of unknown etiology, even outside known areas of prevalence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537021     DOI: 10.1007/bf00183427

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Retinal vasculitis in human T-lymphotropic virus type I associated myelopathy.

Authors:  K Sasaki; I Morooka; H Inomata; N Kashio; T Akamine; M Osame
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

2.  Uveitis associated with human T-cell lymphotropic virus type I.

Authors:  M Mochizuki; T Watanabe; K Yamaguchi; K Yoshimura; S Nakashima; M Shirao; S Araki; K Takatsuki; S Mori; N Miyata
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

3.  Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA.

Authors:  R F Khabbaz; J M Douglas; F N Judson; R A Spiegel; M E St Louis; W Whittington; T M Hartley; M Lairmore; J E Kaplan
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

4.  Noninfectious anterior uveitis in patients infected with human T-lymphotropic virus type I.

Authors:  K Nakao; N Ohba; M Matsumoto
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

5.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

6.  Necropsy findings in HTLV-I associated myelopathy.

Authors:  S Akizuki; O Nakazato; Y Higuchi; K Tanabe; M Setoguchi; S Yoshida; Y Miyazaki; S Yamamoto; S Sudou; K Sannomiya
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

7.  Prevalence of possible adult T-cell leukemia virus-carriers among volunteer blood donors in Japan: a nation-wide study.

Authors:  Y Maeda; M Furukawa; Y Takehara; K Yoshimura; K Miyamoto; T Matsuura; Y Morishima; K Tajima; K Okochi; Y Hinuma
Journal:  Int J Cancer       Date:  1984-06-15       Impact factor: 7.396

8.  Ocular manifestations in patients infected with human T-lymphotropic virus type I.

Authors:  N Ohba; M Matsumoto; M Sameshima; Y Kabayama; K Nakao; K Unoki; F Uehara; K Kawano; I Maruyama; M Osame
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

9.  Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis.

Authors:  K Yoshimura; M Mochizuki; S Araki; N Miyata; K Yamaguchi; K Tajima; T Watanabe
Journal:  Am J Ophthalmol       Date:  1993-08-15       Impact factor: 5.258

10.  Seroprevalence of antibodies to HTLV-I in patients with ocular disorders.

Authors:  K Nakao; M Matsumoto; N Ohba
Journal:  Br J Ophthalmol       Date:  1991-02       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.